Veru enrolls first patient in phase 3 clinical trial of sabizabulin (veru-111) in high risk hospitalized covid-19 patients

—sabizabulin is a novel oral agent with both anti-viral and anti-inflammatory activities—
VERU Ratings Summary
VERU Quant Ranking